The Danish Agency for Science, Technology and Innovation has given over DKK 18m (USD 3.4m) in support funding for a research consortium to develop tests to establish whether generic medicines can produce the same effect as original branded medicines, reports professional journal Ingeniøren (The Engineer).
The new funding brings the total research up to DKK 40m (USD 7.5m), which will be used to acquire greater knowledge on how active ingredients in medicines interact with auxiliary substances used for example to ensure that the active substance is released in the right place and at the right rate.
Consortium leader Thomas Lars Andresen commented to Ingeniøren: "There is currently considerable resistance to using generic medicines, since one cannot be sure that they have exactly the same action because even though the active substance may be the same, the formulation may not be identical."
The research consortium aims to fill in the knowledge gaps in this area and create new tools that can be used to compare generic and branded original medicines.
"When we develop drugs today, we build the formulation on empirical knowledge and traditions regarding which drugs and auxiliary substances should be put together. There isn't a great deal of knowledge about what exactly happens at the molecular level, and how substances interact," says Thomas Lars Andresen.
The research consortium will begin by studying the interaction between components of pharmaceutical formulations at the micro- and nano-scale.